In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CollaGenex Pharmaceuticals Inc.

Division of Nestle SA
www.collagenex.com

Latest From CollaGenex Pharmaceuticals Inc.

Has Orthovita's Fight Finally Ended?

Orthovita had spent the past eight years building up a small commercial pipeline while it ran its flagship bone augmentation material Cortoss through years of a demanding clinical trial. But two months after the FDA approved the product, the company had to clear another unforeseen hurdle: two controversial clinical trials.
Medical Device

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2008

Highlights from the Q1 2008 review of pharmaceutical and biotechnology dealmaking: there was a drought in biopharma financings--particularly from the public markets with only two completed IPOs--but VC funding was strong and made up 40% of the total. M&A activity was also down and saw only one multi-billion dollar deal. In alliances, oligonucleotides were the subject of seven biopharmaceutical collaborations and accounted for most of the quarter's dealmaking money.
BioPharmaceutical

Supernus Pharmaceuticals Inc.

In the early part of this decade, Shire Laboratories was the engine that drove much of Shire PLC's success. The drug delivery unit, which specialized in oral formulations, played a key role in developing many of Shire's top products. Those technologies, as well as existing partnerships, now reside at Supernus Pharmaceuticals, which intends to turn Shire's former drug delivery business into a fully integrated, CNS-focused specialty pharmaceuticals firm.
BioPharmaceutical Strategy

Novel Marketing Models for Mid-Sized Companies: Co-operating to Compete

Mid-sized European companies attempting to compete with Big Pharma's increasingly dominant sales forces in the European primary care arena might consider following Altana Pharma and Solvay Healthcare's lead. A novel cross-promotional agreement comprising a detail-time swap in the UK in theory allows each company to boost its share of voice in its target indication-at practically no extra cost.
BioPharmaceutical Europe
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register